Meeting
2023 ASCO Genitourinary Cancers Symposium
Sexual function after primary external beam radiation therapy (EBRT) for prostate cancer in a large cohort of men with long-term follow-up.
Authors
Domenique Escobar
University of California, San Francisco, San Francisco, CA
Domenique Escobar , Lufan Wang , Jasmin Banton , Janet E. Cowan , Samuel L. Washington III, Osama Mohamad , Peter Carroll
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 346)
DOI
10.1200/JCO.2023.41.6_suppl.346
Abstract #
346
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer.
First Author: Daniel Taussky
Poster
2013 Genitourinary Cancers Symposium
Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy.
First Author: Stephen J. Freedland
Poster
2022 ASCO Genitourinary Cancers Symposium
Genomic instability is enriched in localized prostate cancers from men of African ancestry.
First Author: Jones T. Nauseef
Poster
2021 ASCO Annual Meeting
The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.
First Author: Andrew J. Armstrong